Drug Trial Radar · NCT03835949
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
Last checked: Nov 19, 2026Latest source record: Apr 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
36
Planned (sponsor's estimate)
Start
Jul 16, 2019
Primary completion
Jun 2022
Study completion Jun 2022
Sponsor
- Lead sponsor
- Tracon Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.
Conditions
- Solid Tumor
- Metastatic Cancer
Interventions
TJ004309Drug
Antibody to CD73
AtezolizumabDrug
Humanized monoclonal antibody to PD-L1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerate Dose of TJ004309 plus AtezolizumabTime frame: Approximately 2-8 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
HonorHealth Research Institute
Scottsdale, Arizona
City of Hope
Duarte, California
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.